{"title":"欧洲疫苗接种联盟呼吁医护人员接种COVID-19疫苗","authors":"Stephanie Kohl","doi":"10.1136/ejhpharm-2021-002830","DOIUrl":null,"url":null,"abstract":"Updates from the European Medicines Agency The European Medicines Agency (EMA) published a direct to healthcare professional communication for Vaxzevria (previously COVID-19 Vaccine AstraZeneca), a plain-language description of medical terms related to medicines use and communications advising against the use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials and on the precautionary marketing suspension of the thalassaemia medicine Zynteglo Following recent media reports and publications on the use of ivermectin, EMA reviewed the latest published evidence from laboratory studies, observational studies, clinical trials and meta-analyses Precautionary marketing suspension of thalassaemia medicine Zynteglo The company that markets the gene therapy medicine Zynteglo for treating the rare blood condition beta thalassaemia has suspended sales pending investigation of a safety concern MDR infographic – identifying medical device software Medical devices are an essential part of the delivery of high-quality healthcare and their procurement and management in the European hospital setting is often under the authority of hospital pharmacist","PeriodicalId":11998,"journal":{"name":"European Journal of Hospital Pharmacy","volume":"2 1","pages":"179 - 180"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The European coalition for vaccination calls on healthcare professionals to get vaccinated against COVID-19\",\"authors\":\"Stephanie Kohl\",\"doi\":\"10.1136/ejhpharm-2021-002830\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Updates from the European Medicines Agency The European Medicines Agency (EMA) published a direct to healthcare professional communication for Vaxzevria (previously COVID-19 Vaccine AstraZeneca), a plain-language description of medical terms related to medicines use and communications advising against the use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials and on the precautionary marketing suspension of the thalassaemia medicine Zynteglo Following recent media reports and publications on the use of ivermectin, EMA reviewed the latest published evidence from laboratory studies, observational studies, clinical trials and meta-analyses Precautionary marketing suspension of thalassaemia medicine Zynteglo The company that markets the gene therapy medicine Zynteglo for treating the rare blood condition beta thalassaemia has suspended sales pending investigation of a safety concern MDR infographic – identifying medical device software Medical devices are an essential part of the delivery of high-quality healthcare and their procurement and management in the European hospital setting is often under the authority of hospital pharmacist\",\"PeriodicalId\":11998,\"journal\":{\"name\":\"European Journal of Hospital Pharmacy\",\"volume\":\"2 1\",\"pages\":\"179 - 180\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Hospital Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ejhpharm-2021-002830\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2021-002830","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The European coalition for vaccination calls on healthcare professionals to get vaccinated against COVID-19
Updates from the European Medicines Agency The European Medicines Agency (EMA) published a direct to healthcare professional communication for Vaxzevria (previously COVID-19 Vaccine AstraZeneca), a plain-language description of medical terms related to medicines use and communications advising against the use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials and on the precautionary marketing suspension of the thalassaemia medicine Zynteglo Following recent media reports and publications on the use of ivermectin, EMA reviewed the latest published evidence from laboratory studies, observational studies, clinical trials and meta-analyses Precautionary marketing suspension of thalassaemia medicine Zynteglo The company that markets the gene therapy medicine Zynteglo for treating the rare blood condition beta thalassaemia has suspended sales pending investigation of a safety concern MDR infographic – identifying medical device software Medical devices are an essential part of the delivery of high-quality healthcare and their procurement and management in the European hospital setting is often under the authority of hospital pharmacist